Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma
EMERYVILLE, WIRE)–Eureka Therapeutics, a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced the publication of a study in the New England Journal of Medicine entitled “GPRC5D-Targeted CAR T Cells for The study…
Read More